Isomorphic Labs, Alphabet's AI-driven drug discovery company, is negotiating a funding round of approximately $5 billion that would value the firm at around $50 billion. The talks are not yet finalized, and details remain subject to change.
Spun out of Google DeepMind in 2021, Isomorphic Labs leverages the AlphaFold protein structure prediction model for drug discovery. In May 2026, the company closed a $2.1 billion round led by Thrive Capital with participation from Alphabet and other investors.
Alphabet's Isomorphic Labs in Talks to Raise ~$5 Billion at $50 Billion Valuation
Disclaimer: The content provided on Phemex News is for informational purposes only. We do not guarantee the quality, accuracy, or completeness of the information sourced from third-party articles. The content on this page does not constitute financial or investment advice. We strongly encourage you to conduct you own research and consult with a qualified financial advisor before making any investment decisions.